Gupta Dikshat Gopal, Varma Neelam
Department of Urology and Pathology, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA.
Department of Neurology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Mol Diagn Ther. 2025 May;29(3):329-344. doi: 10.1007/s40291-025-00775-9. Epub 2025 Mar 28.
Acute lymphoblastic leukemia (ALL) is a complex hematologic disorder primarily affecting children, characterized by genetic mutations that disrupt normal lymphoid cell differentiation and promote abnormal proliferation. A particularly high-risk subtype, Philadelphia chromosome-like ALL (Ph-like ALL), mirrors the genetic profile of Philadelphia chromosome-positive (Ph-positive) ALL but lacks the BCR::ABL1 fusion gene. While Ph-like ALL has been extensively studied in high-income countries (HICs), it remains under-researched in low- and middle-income countries (LMICs), where resource limitations hinder accurate diagnosis and targeted therapy. This review addresses this gap by providing a comprehensive overview of the incidence, genetic landscape, and detection strategies for Ph-like ALL, with a special focus on LMICs. It underscores the prevalence of Ph-like ALL and its association with poor clinical outcomes, emphasizing the critical need for cost-effective diagnostic methodologies tailored to resource-constrained settings. Despite advancements in diagnostic technologies, such as whole gene expression profiling and next-generation sequencing, their high cost and extended turnaround times limit their feasibility in LMICs. Innovative methods, such as the PGIMER In-House Rapid and Cost-Effective (PHi-RACE) classifier, which employs real-time quantitative polymerase chain reaction (PCR), offer promising solutions by delivering high sensitivity and specificity at a significantly reduced cost. This approach is further complemented using fluorescence in situ hybridization (FISH) to characterize kinase alterations, enabling the identification of targeted therapies. This method addresses the urgent need for accessible diagnostic tools in LMICs, enabling early detection and personalized treatment planning. As the landscape of Ph-like ALL detection evolves, integrating low-cost, rapid-turnaround approaches holds significant promise for improving patient outcomes globally. This review aims to highlight the challenges and opportunities in diagnosing and treating Ph-like ALL in LMICs, fostering efforts towards more accessible and effective diagnostic strategies to enhance patient care and prognosis.
急性淋巴细胞白血病(ALL)是一种主要影响儿童的复杂血液系统疾病,其特征是基因突变会破坏正常淋巴细胞分化并促进异常增殖。一种特别高危的亚型,即费城染色体样ALL(Ph样ALL),与费城染色体阳性(Ph阳性)ALL的基因特征相似,但缺乏BCR::ABL1融合基因。虽然Ph样ALL在高收入国家(HICs)已得到广泛研究,但在低收入和中等收入国家(LMICs)仍研究不足,因为资源限制阻碍了准确诊断和靶向治疗。本综述通过全面概述Ph样ALL的发病率、基因格局和检测策略来填补这一空白,特别关注低收入和中等收入国家。它强调了Ph样ALL的患病率及其与不良临床结果的关联,强调迫切需要针对资源受限环境量身定制具有成本效益的诊断方法。尽管诊断技术有所进步,如全基因表达谱分析和下一代测序,但它们的高成本和较长的周转时间限制了其在低收入和中等收入国家的可行性。创新方法,如采用实时定量聚合酶链反应(PCR)的PGIMER内部快速且经济高效(PHi-RACE)分类器,通过以显著降低的成本提供高灵敏度和特异性,提供了有前景的解决方案。使用荧光原位杂交(FISH)来表征激酶改变进一步补充了这种方法,从而能够识别靶向治疗。这种方法满足了低收入和中等收入国家对可及诊断工具的迫切需求,能够实现早期检测和个性化治疗规划。随着Ph样ALL检测格局的演变,整合低成本、周转快的方法对于改善全球患者预后具有重大前景。本综述旨在突出低收入和中等收入国家在诊断和治疗Ph样ALL方面的挑战和机遇,推动努力采用更易获得且有效的诊断策略,以改善患者护理和预后。